Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT03071757 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03071757
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03071757 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Completed
Start date
March 21, 2017
Completion date
April 13, 2022
Enrollment
139 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors cancer